mesalamine extended-release capsules / Generic mfg. - LARVOL DELTA

Morris H. Aprison (1923-2007). (PubMed, J Neurol) - No abstract available

Journal

Liver fibrosis scores and coronary artery ectasia. (PubMed, Kardiologiia) - "APRI, FIB-4, NAFLD, and Bard scores are associated with CAE."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Non-alcoholic Fatty Liver Disease

Expanded table: Some drugs for inflammatory bowel disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Drugs for inflammatory bowel disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

US FDA gives final approval for Mesalamine extended-release capsules (ExpressPharma) - "The US Food and Drug Administration (FDA) today gave final approval to Alembic Pharma for its Abbreviated New Drug Application (ANDA) for Mesalamine extended-release capsules USP, 0.375 g, a statement from Alembic Pharma has notified. According to the statement, Mesalamine extended-release capsules are indicated for the maintenance of remission of ulcerative colitis in adults. The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Apriso extended-release capsules, 0.375 g, of Salix Pharma."

ANDA • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Factors Associated With Delayed Corticosteroid Treatment for Patients With Acute Flares in Inflammatory Bowel Disease and Hospital Outcomes (ACG 2022) - "Of the 257 patients, 46.7% were males, mean age was 44.5 years, and 66% had Crohn's disease. One hundred fifty-eight patients (61.5%) received steroids within 24h, 51 (19.8%) 24-48h, 26 (10.1%) 48-72h, and 22 (8.6%) >72h. Fever, diarrhea, and elevated ESR and CRP were more prevalent in patients who received steroids within 48-72h (p= 0.0208, 0.0367, 0.0117, and 0.0163, respectively) compared to those who received steroids within 24h, but not any other time frame ."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Oncology • Pain • CRP • TNFA

"FDA approves Sun Pharmaceuticals’ generic mesalamine extended-release capsules for UC https://t.co/nkY0In1qvu" (@IBD_FloMD)

FDA event

FDA Approves Generic Mesalamine Extended Release Capsules for Ulcerative Colitis (Pharmacy Times) - "The FDA has approved an Abbreviated New Drug Application (ANDA) from Sun Pharmaceutical Industries Limited for generic Mesalamine Extended Release Capsules 500 mg. The approval of the ANDA for the generic product was based on the reference product Pentasa Extended Release Capsules, 500mg."

ANDA • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

"Looks like Apriso dose is too low on their site. No?" (@GI_Pearls)

Ozanimod (Zeposia) for ulcerative colitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Zydus Cadila receives final approval from US FDA for Mesalamine Extended-Release capsules (ExpressPharma) - "Zydus Cadila has received the final approval from the US Food and Drug Administration (FDA) to market Mesalamine Extended-Release capsules in the strength of 0.375 g, (US RLD: Apriso), the company notified in a statement. Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults."

ANDA • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

"ReTweet Blood On The Razor Wire TV YouTube. @shonhopwood @SbPhoenixRae @Sbleaf @KillerMike @LynnSosnoskie @HelenBranswell @LarryGlickman @JailbreakHackz @SallyGold @Rampage4real @RespectableLaw @aprisondiary @PrisonPandemic @prison_walls @Survivingfree" (@ChadMarks19)

COVID-19 in IBD: The experience of a single tertiary IBD center. (PubMed, Dig Liver Dis) - "Our data are in line with the current literature and confirm a higher incidence compared to the general population. Biological therapy for IBD seems to not be a risk factor for infection and should not be discontinued in order to avoid IBD relapse."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Novel Coronavirus Disease

Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. (PubMed, Trials) - "This is the first randomized controlled clinical study protocol regarding Chinese herbal extract granules in the management of moderately active UC. We aim to investigate the superiority of QCHS granules over placebo in terms of induction of remission. If the trial shows significant benefits of QCHS granules, it will help clinical practitioners, UC patients, and policymakers make more informed choices in the decision-making."

Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

"New meta-analysis on mesalazine in UC in JCC 🏂#uegedu @myueg @aeg @geteccu @NTNUikom 💡" (@ign76)

Retrospective data

Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. (PubMed, World J Gastroenterol) - "Obese IBD patients seem to have features similar to general obese population, and there is no disease-specific factor (disease activity, extension or therapy) that may foster obesity in IBD."

Clinical • Journal • Addiction (Opioid and Alcohol) • Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Obesity • Pulmonary Arterial Hypertension • Type 2 Diabetes Mellitus • Ulcerative Colitis

Advanced Real-Time Process Analytics for Multistep Synthesis in Continuous Flow. (PubMed, Angew Chem Int Ed Engl) - "We report the integration of four complementary process analytical technology tools (NMR, UV/vis, IR and UHPLC) in the multistep synthesis of an active pharmaceutical ingredient, mesalazine...Advanced data analysis models were developed (indirect hard modelling, deep learning and partial least squares regression), to quantify the desired products, intermediates and impurities in real time, at multiple points along the synthetic pathway. The capabilities of the system have been demonstrated by operating both steady state and dynamic experiments and represents a significant step forward in data-driven continuous flow synthesis."

Journal

Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. (PubMed, J Crohns Colitis) - "Our results support previous evidence, however, higher doses of oral mesalazine had more evidence for induction of remission than combined therapy and were significantly more efficacious than lower doses. Future RCTs should better establish the role of combined therapy for induction of remission, as well as optimal doses of oral 5-ASAs to prevent relapse."

Journal • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Administration of neem (Azadirachta indica A. Juss) leaf extract decreases TNF-α and IL-6 expressions in dextran sodium sulfate-induced colitis in rats. (PubMed, J Adv Vet Anim Res) - "In the second phase, 84 colitis rats were divided into groups I, II, and III receiving 7.8 mg/day of mesalazine, 100 mg/200 gm body weight, and 200 mg/200 gm body weight neem leaf extract, respectively...TNF-α and IL-6 expressions in group III were comparable with group I since the second week. This condition was observed in the 4th week between group II and group I. It can be concluded that neem leaf extract decreased the expression of TNF-α and IL-6 in DSS-induced colitis."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • IL6 • TNFA

Impact of Demographic, Clinical and Psychosocial Variables on Drug Adherence and Outcomes in Indian Patients With Inflammatory Bowel Disease: Cost is not the Only Factor! (PubMed, J Clin Gastroenterol) - "Nonadherence is common in Indian IBD patients but adherence is associated with improved QoL and lower probability of relapse. Psychosocial and medication-related factors are important determinants of adherence compared with demographic or clinical variables and should be addressed."

Clinical • Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Levels of major and trace metals in the scalp hair of Crohn's disease patients: correlations among transition metals. (PubMed, Biometals) - "Thus, the majority of the Fe, Cr, and Co in the serum of CD patients is likely to bind to transferrin, which may be associated with the higher concentrations of those metals, as well as the significant correlations among those metals in the scalp hair of CD patients. In addition, colectomy may alter the intestinal absorption rate of some metals, while mesalazine may increase the concentrations of Mn and some metals in the scalp hair by chelate formation."

Clinical • Journal • Crohn's disease • Gastroenterology • Hematological Disorders • Immunology • Inflammatory Bowel Disease

Ultraperformance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics and Lipidomics Identify Biomarkers for Efficacy Evaluation of Mesalazine in a Dextran Sulfate Sodium-Induced Ulcerative Colitis Mouse Model. (PubMed, J Proteome Res) - "Among them, four potential biomarkers (palmitoyl glucuronide, isobutyrylglycine, PC (20:3 (5Z, 8Z, 11Z)/15:0) and L-arginine) had a signficantly reversed level of peak areas in the mesalazine group, and three of them were closely correlated with mesalazine efficacy by linear regression analysis. Furthermore, metabolic pathway analysis revealed several dysregulated pathways in colitis mice, including glycerophospholipid metabolism, pyrimidine metabolism, linoleic acid metabolism, arginine biosynthesis, etc. This study indicates that serum metabolomics is a useful approach that can noninvasively evaluate the therapeutic effect and provide unique insights into the underlying mechanism of mesalazine."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Ulcerative Colitis • TNFA

Dilodendron bipinnatum Radlk. extract alleviates ulcerative colitis induced by TNBS in rats by reducing inflammatory cell infiltration, TNF-α and IL-1β concentrations, IL-17 and COX-2 expressions, supporting mucus production and promotes an antioxidant effect. (PubMed, J Ethnopharmacol) - "HEDb reduces colonic damage in the TNBS colitis model and relieves oxidative and inflammatory events, at least in part, by increasing mucus production, reducing leukocyte migration and reducing TNF-α (in vivo and in vitro), IL-1β, IL-17 and COX-2 expression. Therefore, HEDb requires further investigation as a candidate for treating IBD."

Journal • Colorectal Adenocarcinoma • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Oncology • Pain • Ulcerative Colitis • CXCL8 • IL17A • IL1B • MPO • TNFA

Tissue-based biosensor for monitoring the antioxidant effect of orally administered drugs in the intestine. (PubMed, Bioelectrochemistry) - "We found that the O production by catalase from HO was reduced in the presence of a well-known antioxidant, quinol. This indirectly detected antioxidant activity was also observed in the case of orally administered drugs with a reported anti-inflammatory effect such as mesalazine and paracetamol, while no antioxidant activity was recorded with aspirin and metformin."

Journal • CAT

Intestinal concentrations and efficacy of different mesalazine tablets in patients with ulcerative colitis. Valutazioni delle concentrazioni intestinali e dell'efficacia di diverse compresse di mesalazina in paziente con colite ulcerosa. (clinicaltrialsregister.eu) - P4; N=36; Completed; Sponsor: CONSORZIO UNIVERSITARIO UNIFARM

Clinical • New P4 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis